Sanofi-Aventis (SNY) says breast cancer treatment BSI-201, a key drug in its development...

|About: Sanofi (SNY)|By:, SA News Editor

Sanofi-Aventis (SNY) says breast cancer treatment BSI-201, a key drug in its development pipeline, failed to meet its goal in a late-stage study. SNY -4.2% premarket. (PR)